EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metabolic dysfunction-associated steatotic liver disease (MASLD): emerging insights into gut microbiota interactions and therapeutic perspectives

Wenchu Qian, Ling He, Chenxue Fu, Tiantian Zeng, Hanyu Wang, Haifang Li

Exploration of Digestive Diseases · 2025

DOI: 10.37349/edd.2025.100579 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Exploration of Digestive Diseases, 2025. Verfasst von Wenchu Qian und 5 weiteren Autor:innen. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As the most prevalent hepatic disorder worldwide, metabolic dysfunction-associated steatotic liver disease (MASLD) afflicts over one-third of the global population, representing a significant public health challenge. The multifactorial pathogenesis of this condition is principally rooted in metabolic dysregulation. It is notable that emerging evidence highlights a critical role for gut microbiota (GM) in disease initiation and progression. This comprehensive review elaborates some representative GM species that influence hepatic lipid metabolism and elucidates the mechanisms through which GM dysbiosis exacerbates MASLD pathogenesis. Importantly, the positive or negative effects of intestinal bacterial communities on MASLD are largely dependent on their special metabolites, such as short chain fatty acids, ethanol, and trimethylamine N-oxide. Current therapeutic strategies targeting GM modulation, including prebiotics, probiotics, fecal microbiota transplantation, specific medicines, and bacteriphages, demonstrate promising efficacy that partially restores microbial equilibrium and mitigates hepatic steatosis. Although limitations still persist in achieving sustained clinical remission, the expanding frontier of microbiome research continues to refine our understanding of host-microbiota crosstalk in MASLD. Future investigations integrating multiple approaches and longitudinal clinical data hold potential to unravel complex microbial networks, paving the way for innovative therapeutic breakthroughs in metabolic liver disease management.

Zitieren

APA

Qian, W., He, L., Fu, C., Zeng, T., Wang, H., & Li, H. (2025). Metabolic dysfunction-associated steatotic liver disease (MASLD): emerging insights into gut microbiota interactions and therapeutic perspectives. Exploration of Digestive Diseases. https://doi.org/10.37349/edd.2025.100579

Vancouver

Qian W, He L, Fu C, Zeng T, Wang H, Li H. Metabolic dysfunction-associated steatotic liver disease (MASLD): emerging insights into gut microbiota interactions and therapeutic perspectives. Exploration of Digestive Diseases. 2025. doi:10.37349/edd.2025.100579

BibTeX
@article{Qian2025,
  author = {Qian, Wenchu and He, Ling and Fu, Chenxue and Zeng, Tiantian and Wang, Hanyu and Li, Haifang},
  title = {Metabolic dysfunction-associated steatotic liver disease (MASLD): emerging insights into gut microbiota interactions and therapeutic perspectives},
  journal = {Exploration of Digestive Diseases},
  year = {2025},
  doi = {10.37349/edd.2025.100579}
}
Kostenlos starten →